TY - JOUR
T1 - Functional Characterization of an IL2RG Variant, a Case Report of X-Linked T- B + NK + SCID
AU - Assing, Kristian
AU - Christensen, Emil Birch
AU - Dellgren, Christoffer
AU - Soelberg, Kerstin Kathrine
AU - Fagerberg, Christina
AU - Elle, Ida Coordt
AU - Larsen, Bjørk Ditlev
AU - Grosen, Dorthe
AU - Booth, Claire
AU - Marquart, Hanne Vibeke
AU - Masmas, Tania Nicole
AU - Hartling, Hans Jakob
N1 - Publisher Copyright:
© 2025 The Author(s). Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.
PY - 2025/12
Y1 - 2025/12
N2 - Objectives: Pathogenic variants in IL2RG, encoding the common γ chain (γc/CD132), usually lead to T − B + NK- X-SCID but can, occasionally, generate a T − B + NK+ phenotype. We wanted to delineate potential mechanisms for this discrepancy. Methods: The immunological work-up of our patient comprised: whole genome sequencing and subsequent bioinformatics, flow-cytometry (lymphocyte surface receptor expression, STAT5 phosphorylation, NK cell proliferation and degranulation), lymphocyte stimulation (IL-2, IL-4 and IL-15) as well as restriction enzyme digestion and fragment size separation (evaluation of relative WT/variant expression). Findings: Our patient, hemizygous for a maternally derived, c.677 G > A IL2RG missense variant displayed a T − B + NK+ phenotype, no dysmorphic features and no thymus. The γc was surface expressed. In contrast to B cells from cord-blood and adults (including maternal B cells), only pre-gene therapy (patient) B cells did not decrease IL-4Rα surface expression upon IL-4 stimulation, consistent with compromised IL-4R (and γc) function. After gene therapy, patient B cells decreased IL-4Rα upon Il-4 stimulation. Pre-gene therapy NK cells displayed normal, K562 cell, induced degranulation and, in response to IL-2 and IL-15 and exhibited normal initial pSTAT5 kinetics but clearly attenuated activation and proliferation day six. By restriction enzyme digestion and fragment size separation, selected T and B cells from the healthy mother exhibited skewed expression (92% and 84%, respectively) of the WT IL2RG allele. Conclusion: The selective WT IL2RG expression in maternal B cells was consistent with the compromised IL-4R signaling (and compromised IL-21R signaling) in her offspring (the patient), as both IL-4 and IL-21 are critical for normal human B cell germinal center reactions but not for peripheral B cell homeostasis. The c.677 G > A IL2RG variant permitted normal NK cell degranulation and initial STAT5 phosphorylation but was incapable of sustaining normal NK cell activation and proliferation in vitro. As IL-2 and IL-15 induced in-vitro NK cell proliferation is primarily mediated through the low affinity βγc (CD122-CD132) complex, our data indicate the importance of high affinity IL-15Rα and IL-2 Rα mediated signaling in-vivo for sustaining NK cell numbers in X-linked SCID. Consequently, we further hypothesize that in cases of X-linked SCID, where even initial IL-15 and IL-2 STAT5 phosphorylation is compromised, in-vivo trans-presentation of IL-15 (and IL-2), via the high affinity IL-15Rα and IL-2Rα receptor subunits, will not be able to sustain normal peripheral NK cell numbers”.
AB - Objectives: Pathogenic variants in IL2RG, encoding the common γ chain (γc/CD132), usually lead to T − B + NK- X-SCID but can, occasionally, generate a T − B + NK+ phenotype. We wanted to delineate potential mechanisms for this discrepancy. Methods: The immunological work-up of our patient comprised: whole genome sequencing and subsequent bioinformatics, flow-cytometry (lymphocyte surface receptor expression, STAT5 phosphorylation, NK cell proliferation and degranulation), lymphocyte stimulation (IL-2, IL-4 and IL-15) as well as restriction enzyme digestion and fragment size separation (evaluation of relative WT/variant expression). Findings: Our patient, hemizygous for a maternally derived, c.677 G > A IL2RG missense variant displayed a T − B + NK+ phenotype, no dysmorphic features and no thymus. The γc was surface expressed. In contrast to B cells from cord-blood and adults (including maternal B cells), only pre-gene therapy (patient) B cells did not decrease IL-4Rα surface expression upon IL-4 stimulation, consistent with compromised IL-4R (and γc) function. After gene therapy, patient B cells decreased IL-4Rα upon Il-4 stimulation. Pre-gene therapy NK cells displayed normal, K562 cell, induced degranulation and, in response to IL-2 and IL-15 and exhibited normal initial pSTAT5 kinetics but clearly attenuated activation and proliferation day six. By restriction enzyme digestion and fragment size separation, selected T and B cells from the healthy mother exhibited skewed expression (92% and 84%, respectively) of the WT IL2RG allele. Conclusion: The selective WT IL2RG expression in maternal B cells was consistent with the compromised IL-4R signaling (and compromised IL-21R signaling) in her offspring (the patient), as both IL-4 and IL-21 are critical for normal human B cell germinal center reactions but not for peripheral B cell homeostasis. The c.677 G > A IL2RG variant permitted normal NK cell degranulation and initial STAT5 phosphorylation but was incapable of sustaining normal NK cell activation and proliferation in vitro. As IL-2 and IL-15 induced in-vitro NK cell proliferation is primarily mediated through the low affinity βγc (CD122-CD132) complex, our data indicate the importance of high affinity IL-15Rα and IL-2 Rα mediated signaling in-vivo for sustaining NK cell numbers in X-linked SCID. Consequently, we further hypothesize that in cases of X-linked SCID, where even initial IL-15 and IL-2 STAT5 phosphorylation is compromised, in-vivo trans-presentation of IL-15 (and IL-2), via the high affinity IL-15Rα and IL-2Rα receptor subunits, will not be able to sustain normal peripheral NK cell numbers”.
KW - B cells
KW - case report
KW - NK cells
KW - pSTAT5
KW - X-SCID
UR - http://www.scopus.com/inward/record.url?scp=105026158272&partnerID=8YFLogxK
U2 - 10.1002/iid3.70307
DO - 10.1002/iid3.70307
M3 - Journal article
C2 - 41462576
AN - SCOPUS:105026158272
SN - 2050-4527
VL - 13
JO - Immunity, Inflammation and Disease
JF - Immunity, Inflammation and Disease
IS - 12
M1 - e70307
ER -